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SUMMARY
BACKGROUND—The Xpert® MTB/RIF assay can diagnose tuberculosis (TB) rapidly and with 
great accuracy. The effect of Xpert placement at point of care (POC) vs. at an off-site laboratory 
on patient management remains unknown.
DESIGN—At a primary care clinic in Johannesburg, South Africa, we compared TB diagnosis 
and treatment initiation among 1861 individuals evaluated for pulmonary TB using Xpert 
performed either at POC or offsite.
RESULTS—When Xpert was performed at POC, a higher proportion of Xpert-positive 
individuals started treatment (95% vs. 87%, P = 0.047) and time to treatment initiation was shorter 
(median 0 vs. 5 days, P < 0.001). In contrast, among Xpert-negative TB cases, a higher proportion 
(87% vs. 72%, P =0.001) started treatment when the sample was sent to the laboratory, with a 
shorter time to treatment (median 9 vs. 13 days, P = 0.056). While the overall proportion of 
presumed TB patients starting treatment was independent of Xpert placement, the proportion 
started based on a bacteriologically confirmed diagnosis was higher when Xpert was performed at 
POC (73% vs. 58%, P = 0.006).
CONCLUSIONS—Placement of Xpert at POC resulted in more Xpert-positive patients receiving 
treatment, but did not increase the total number of presumed TB patients starting treatment. When 
samples were sent to a laboratory for Xpert testing, empiric decision making increased.
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IMPROVING THE AVAILABILITY, accuracy and speed of tuberculosis (TB) diagnosis has 
the potential to reduce transmission and hasten the decline of incidence rates, particularly in 
high-burden settings.1,2 The Xpert® MTB/RIF (Cepheid, Sunnyvale, CA, USA) assay has 
improved diagnostic accuracy compared to smear microscopy,3 and can deliver results in 2 h 
at point of care (POC).4 POC placement of Xpert has been demonstrated to be feasible, 
facilitating same-day initiation of anti-tuberculosis treatment.5–7
The South African Department of Health (DOH), together with the National Health 
Laboratory Service (NHLS), has been a global leader in rolling out the Xpert assay and 
replacing smear microscopy with Xpert as the initial diagnostic for all individuals with 
presumptive TB.8,9 Based on logistical and financial considerations, Xpert instruments were 
placed in NHLS laboratories performing smear microscopy rather than at POC in clinics. 
The transportation of samples to laboratories creates a diagnosis–treatment gap due to the 
delay in the availability of results, which increases the risk of loss to follow-up during the 
diagnostic process. This may undermine the huge potential of this new technology to 
improve patient outcomes.10
Two randomised controlled trials have compared patient outcomes when using Xpert vs. 
smear microscopy, either sending all samples to a laboratory (XPert for TB: Evaluating a 
New Diagnostic Trial, or EXTEND TB) or performing both Xpert and smear microscopy at 
POC (TB diagnosis in smear-negative and HIV-infected persons in high-burden countries, or 
the TB NEAT study).7,11 While these studies assessed the incremental benefit of Xpert vs. 
smear microscopy, they could not answer the important question of the extent to which 
Xpert placement impacts patient management. We therefore compared TB diagnosis and 
treatment initiation in individuals with presumed pulmonary TB who were assessed by Xpert 
placed at POC or at an offsite laboratory. We hypothesised that Xpert at POC would result in 
a greater proportion of individuals starting treatment compared to laboratory placement.
METHODS
Participants in this prospective cohort study received care at the Witkoppen Health and 
Welfare Centre, a primary care clinic in northern Johannesburg. All clinic clients were 
offered provider-initiated human immunodeficiency virus (HIV) counselling and testing, as 
well as screening for TB symptoms. Patients were evaluated for pulmonary TB if they were 
HIV-infected and presented with cough, fever, unintentional weight loss or night sweats of 
any duration, or were non-HIV-infected and presented with prolonged (≥2 weeks) cough, 
fever, night sweats or unintentional weight loss. Clients were referred to a nearby hospital 
for chest X-ray upon clinician request.
From July 2011 to July 2012, Xpert testing was performed in the clinic at the POC using 
two four-module instruments operated by HIV counsellors with high school education or 
lower. Two spontaneous sputum samples were collected: one was processed using POC 
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Xpert, the other was sent to an NHLS laboratory in Johannesburg for fluorescent sputum 
smear microscopy and liquid culture. Xpert assays with invalid results were repeated 
whenever possible using a new sputum sample. In August 2012, POC Xpert was stopped, 
and all samples were transported to the NHLS laboratory for offsite Xpert testing, according 
to the new Department of Health algorithm.12 According to NHLS guidelines, a sample for 
Xpert testing was rejected if submitted within 60 days of a previous sample with a 
successful Xpert result. Xpert results from the NHLS laboratory could be accessed online in 
real time by clinic staff.
Demographic and clinical data on consecutive adults (age ≥15 years) who underwent Xpert 
testing for pulmonary TB were collected from reviews of medical charts, electronic records 
and clinic registers over two 6-month study periods: December 2011–May 2012, when Xpert 
was performed at POC (POC Xpert period), and August 2012–January 2013, when samples 
were sent to a laboratory for Xpert testing (laboratory Xpert period).
The main outcome of interest was initiation of anti-tuberculosis treatment in the 3 months 
following initial sputum collection. Those not initiating treatment by 3 months were 
considered lost to follow-up. Cases who started treatment based on a positive Xpert, smear 
microscopy or culture were classified as bacteriologically confirmed,13 while those who 
started treatment in the absence of, or prior to, any positive bacteriological test were 
classified as empiric treatment. Xpert-negative TB was defined as an individual testing 
negative on Xpert but diagnosed with TB based on smear, culture, X-ray or clinical 
presentation. Time to anti-tuberculosis treatment initiation was defined as the time between 
collection of the initial sputum sample for Xpert testing and treatment initiation. Participants 
with drug resistance detected by any method were excluded from the time-to-treatment 
analysis. Laboratory turnaround times for Xpert were calculated from receipt of the sample 
at the laboratory until test results were authorised for release. Samples without a valid Xpert 
result included those with an invalid result, those that leaked in transit and those rejected by 
the laboratory as a duplicate request if they were submitted as a repeat after an error result or 
leaked sample.
We constructed Kaplan-Meier curves to estimate time to treatment initiation, and compared 
the basis of treatment by study period using a proportions test. We used a Cox proportional 
hazards model to compare time to treatment initiation between study groups among Xpert-
positive individuals. All statistical analyses were conducted using Stata, v 12 (Stata Corp, 
College Station, TX).
The study was approved by the institutional review boards of the University of North 
Carolina, Chapel Hill and the University of the Witwatersrand in Johannesburg, South 
Africa. All participants provided written consent for research use of routinely collected 
clinical data.
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A total of 1861 adults were assessed using Xpert as the initial diagnostic for presumptive 
pulmonary TB. About equal proportions were evaluated by POC Xpert (n =870, 47%) and 
laboratory Xpert (n =991, 53%) (Table 1). Most presented with cough (84%), were female 
(59%) and HIV-infected (72%). Compared to those in the POC Xpert group, individuals 
assessed by laboratory Xpert were more likely to be co-infected with HIV (76% vs. 67%, P 
< 0.001) and be on antiretroviral treatment (ART) (45% vs. 42%, P =0.027). The proportion 
with a CD4 count below the ART initiation threshold of 350 cells/mm3 was similar for both 
groups (59% POC Xpert and 60% laboratory Xpert, P = 0.712).
Turnaround time for Xpert results
The majority of POC Xpert results (84%) were available on the same working day (by 4 
pm), while the remainder (16%) were run overnight, with results available the following day. 
When performed at the laboratory, the majority (58%) of Xpert results were available online 
by the end of the day following sputum collection, and 96% of results were available within 
2 days.
Xpert results, TB diagnosis and treatment initiation
The proportion of those evaluated for TB who tested positive on initial Xpert was similar in 
the two groups, with 11% having a positive result in both the POC Xpert (100/870) and 
laboratory Xpert groups (104/991). The proportion of individuals with rifampicin resistance 
detected using Xpert was relatively low, but was similar in the two groups (POC, 3%; 
laboratory Xpert, 5%; P = 0.467).
The impact of Xpert placement on the cumulative proportion of all TB cases started on anti-
tuberculosis treatment, regardless of diagnostic basis, varied by time since initial evaluation 
(Figure, A). By 5 days following evaluation, 54% (95% confidence interval [CI] 47–60) of 
all TB cases were on treatment in the POC Xpert group compared to 38% (95%CI 32–46) in 
the laboratory Xpert group. However, by 15 days, more laboratory Xpert TB cases were on 
treatment (73%, 95%CI 67–79) than POC Xpert TB cases (63%, 95%CI 56–69). By 90 
days, the gap between the two groups had narrowed (POC Xpert 82%, 95%CI 77–87; 
laboratory Xpert 87%, 95%CI 82–91). The median time to treatment in the POC Xpert 
group was 1 day (interquartile range [IQR] 0–14), while that of the laboratory Xpert group 
was 7 days (IQR 2–12, P < 0.001). More patients were started on treatment on the basis of 
bacteriological confirmation when Xpert was at POC (72%, 95%CI 65–79) vs. offsite at the 
laboratory (58%, 95%CI 48–63, P = 0.002).
Among Xpert-positive patients, a higher cumulative proportion tested using POC Xpert 
(95%, 95%CI 89–98) than those who underwent laboratory-based Xpert (87%, 95%CI 79–
92, P = 0.047) started treatment by 90 days following initial evaluation (Figure, B). Among 
Xpert-positives who started anti-tuberculosis treatment, the median time to treatment with 
POC Xpert was 0 days (IQR 0–1), while with laboratory Xpert it was 5 days (IQR 1–7, P 
<0.001). The proportion of Xpert-positive patients starting treatment on the same day as TB 
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testing was also higher among those assessed using POC Xpert (68/97, 70% vs. 12/99, 12%; 
P < 0.001). Among those who tested positive on laboratory Xpert, 23% (23/99) were started 
on treatment empirically before the Xpert result was available to the clinician. Among 
Xpert-positives, instrument placement was the only variable associated with time to 
treatment initiation in the multivariate Cox proportional hazards model (adjusted hazard 
ratio 0.45, 95%CI 0.33–0.61, P < 0.001, after accounting for age, sex and HIV status, Table 
2), suggesting that Xpert placement at POC resulted in a faster time to treatment initiation, 
independent of patient characteristics, which differed according to study period.
Among Xpert-negative patients, the cumulative proportion started on treatment based on 
clinical examination, smear, culture or chest X-ray was similar in the two groups: 11% 
(95%CI 9–13) in the POC Xpert and 8% (95%CI 7–11) in the laboratory Xpert groups (P = 
0.173). More Xpert-negative TB cases were initiated on treatment during the laboratory 
Xpert period (87%, 95%CI 79–93) than in the POC Xpert period (72%, 95%CI 63–80, P 
=0.001) (Figure, C). Among Xpert-negative TB cases starting anti-tuberculosis treatment, 
the median time to treatment was 13 days (IQR 1–33) in the POC Xpert group and 9 (IQR 
3–18) in the laboratory Xpert group (P = 0.056).
Xpert errors and diagnostic follow-up
The proportion of assays with invalid or error results was similar in both groups: 4% at POC 
and 3% at offsite laboratory (P = 0.238). In addition, 33 (3%) samples leaked during 
transportation to the laboratory and 10 samples were rejected by the laboratory because a 
previous sample had been processed within the past 60 days (Table 3). The overall 
proportion of sputum samples without a valid Xpert result was therefore higher at the 
laboratory than at POC (8% vs. 4%, P < 0.001).
DISCUSSION
In this prospective cohort study, we found that although Xpert placement at POC did not 
increase the overall proportion of presumed TB patients initiating treatment, POC Xpert did 
improve patient management. Almost all (95%) of those testing positive on POC Xpert 
started anti-tuberculosis treatment, mostly on the day of presentation, while 13% of those 
with a positive result in the laboratory Xpert group failed to initiate treatment, resulting in an 
8% decrease in the proportion of cases confirmed by Xpert initiating anti-tuberculosis 
treatment. Empiric treatment was less common in the POC Xpert period than in the 
laboratory Xpert period. POC placement of the Xpert apparatus also altered the management 
of Xpert-negative TB cases, with a lower proportion started on treatment and a longer time 
to treatment initiation than in the case of laboratory placement of Xpert.
Our findings are in line with two recent studies that failed to demonstrate significant impact 
on patients of the use of Xpert when compared to smear microscopy for the initial 
diagnostic.7,11 In a trial where patients were randomised to same-day Xpert at POC vs. 
same-day smear microscopy at POC (TB-NEAT study), no effect was observed on 
morbidity, mortality or the proportion of patients started on treatment.7 However, similar to 
our findings, Xpert improved patient management, with a higher proportion of culture-
confirmed TB cases initiating treatment in the Xpert arm (91% vs. 84%) and a lower 
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proportion initiating empiric treatment in the Xpert arm (17% vs. 26%, P < 0.001). In a 
cluster randomised trial of laboratory-based Xpert vs. laboratory-based smear microscopy 
(EXTEND-TB study), the use of Xpert also did not increase the proportion of presumed TB 
patients started on treatment, and no effect on mortality was observed.11 Taken together, 
these results support the hypothesis proposed by Theron et al. that high rates of empiric 
treatment may reduce the potential positive effect of more accurate or immediate TB 
diagnosis on patient outcomes in high-burden settings.14 In our study, without access to 
same-day Xpert results, clinicians frequently initiated empiric treatment, with 23% of 
patients in the laboratory group initiating treatment empirically, before the positive Xpert 
result became available. The population impact of Xpert at POC will likely depend heavily 
on changes in patient management that accompany its implementation.
It has been demonstrated that the diagnostic accuracy of Xpert when carried out at POC and 
that of Xpert performed at a laboratory were comparable. We found that the proportion of 
Xpert assays with an invalid result was likewise independent of Xpert placement, confirming 
that the assay can be performed in the clinic setting by low-skilled health workers.5–7 
Placement of Xpert at a laboratory created problems related to the transportation of samples 
(3% leaked), and fewer invalid results or errors being repeated.
Despite the strengths of a large sample size and implementation under real-world conditions, 
several limitations should be considered when interpreting these findings. The operational 
nature of our study design did not incorporate rigorously controlled diagnostic processes and 
resulted in the absence of culture results in all participants. Allocation to Xpert at POC or 
laboratory occurred by study period and was not randomised, possibly introducing bias by 
factors other than Xpert placement that may have changed over time. The study was set at a 
single primary care clinic, possibly limiting its generalisability due to clinical practices that 
were particular to this setting. For example, the daily presence of a physician and access to 
X-ray may not be representative of primary care settings in many high TB burden settings. 
The laboratory characteristics may also not have been representative, given the excellent 
infrastructure, including roadways and telecommunications, which allowed twice-daily 
transportation of samples to the laboratory and the electronic relay of results. These clinic 
and laboratory characteristics may have resulted in an underestimation of the effect of Xpert 
placement at POC. Placement of Xpert at POC in settings with fewer resources, lower 
density of laboratories or in rural settings, where patients travel long distances to access care 
and where sample transportation and communication infrastructure is less reliable, may 
result in a greater impact.
In summary, in an urban clinic with good infrastructure, POC placement of Xpert increased 
the health care worker’s ability to rapidly start Xpert-positive patients on treatment and 
avoid loss to follow-up, but did not influence the overall proportion of presumed TB patients 
started on treatment and the time to treatment initiation. When samples were transported to a 
laboratory, empiric anti-tuberculosis treatment was an important form of treatment decision 
making, resulting in greater initiation of treatment in Xpert-negatives. The impact of the 
introduction of new diagnostic tests for TB may depend largely on the diagnostic practices 
and quality of the health care system. In settings with intermittent sample transportation, 
cumbersome communication of test results, low patient access to care or in which empiric 
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treatment is infrequent, the placement of Xpert at POC can be expected to have a greater 
impact on patient outcomes. Economic evaluations and modelling studies that take these 
complexities into account are needed to guide policies on Xpert placement in high-burden 
countries to maximise patient impact.
Acknowledgments
The authors sincerely thank the patients and clinical staff at the Witkoppen Health and Welfare Centre, 
Johannesburg, South Africa, as well as V Modise for assistance in collecting patient data.
This work was supported by the National Institute for Allergy and Infectious Diseases at the National Institutes of 
Health, Bethesda, MD, USA (grant number UM1 AI069463), and the United States Agency for International 
Development, Washington DC, USA (grant number AID-674-A-12-00033).
References
1. Lin HH, Dowdy D, Dye C, Murray M, Cohen T. The impact of new tuberculosis diagnostics on 
transmission: why context matters. Bull World Health Organ. 2012; 90:739–747A. [PubMed: 
23109741] 
2. Sun AY, Pai M, Salje H, Satyanarayana S, Deo S, Dowdy DW. Modeling the impact of alternative 
strategies for rapid molecular diagnosis of tuberculosis in southeast Asia. Am J Epidemiol. 2013; 
178:1740–1749. [PubMed: 24100953] 
3. Steingart KR, Sohn H, Schiller I, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and 
rifampicin resistance in adults. Cochrane Database Syst Rev. 2013; 1:CD009593. [PubMed: 
23440842] 
4. Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a 
new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011; 
6:1067–1082. [PubMed: 21958145] 
5. Clouse K, Page-Shipp L, Dansey H, et al. Implementation of Xpert MTB/RIF for routine point-of-
care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012; 102:805–807. [PubMed: 
23034211] 
6. Hanrahan CF, Selibas K, Deery CB, et al. Time to treatment and patient outcomes among TB 
suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, 
South Africa. PLOS ONE. 2013; 8:e65421. [PubMed: 23762367] 
7. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care 
Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, 
randomised, controlled trial. Lancet. 2014; 383:424–435. [PubMed: 24176144] 
8. National Health Laboratory Service. NPP Implementation of GeneXpert for TB testing. 
Johannesburg, South Africa: NHLS; 2013. http://www.nhls.ac.za/?
page=genexpert_for_tb_testing&id=69 [Accessed March 2015]
9. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment 
guidelines for a public health approach. Geneva, Switzerland: WHO; 2013. 2003 revisionhttp://
www.who.int/3by5/publications/documents/arv_guidelines/en/ [Accessed March 2015]
10. Lawn SD, Kerkhoff AD, Wood R. Location of Xpert® MTB/RIF in centralised laboratories in 
South Africa undermines potential impact. Int J Tuberc Lung Dis. 2012; 16:701. author reply 2. 
[PubMed: 22507934] 
11. Churchyard, G. Effect of Xpert MTB/RIF on early mortality in adults with suspected TB: a 
pragmatic randomized trial. Conference on Retroviruses and Opportunistic Infections (CROI); 
Boston, MA, USA. 3–6 March 2014; [Oral Abstract 95]
12. National Health Laboratory Services. GeneXpert testing algorithm. Johannesburg, South Africa: 
NHLS; 2013. http://www.nhls.ac.za/assets/files/GeneXpert%20poster.pdf [Accessed March 2015]
13. World Health Organization. Definitions and reporting framework for tuberculosis. Geneva, 
Switzerland: WHO; 2013. 2013 revision. WHO/HTM/TB/2013.2
Hanrahan et al. Page 7













14. Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K. Do high rates of empirical treatment 
undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? 
Lancet Infect Dis. 2014; 14:527–532. [PubMed: 24438820] 
Hanrahan et al. Page 8














Estimated time to anti-tuberculosis treatment by Xpert status and Xpert placement. A) All 
patients with a TB diagnosis, regardless of its basis; B) all patients who were Xpert-positive; 
and C) all patients who were diagnosed with Xpert-negative TB. TB=tuberculosis; 
IQR=interquartile range; POC=point of care.
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Table 1






n (%) P value
Age category, years 0.036
 <30 239 (27) 221 (22)
 30–45 416 (48) 505 (51)
 >45 215 (25) 265 (27)
Female sex 506 (58) 597 (60) 0.129
HIV <0.001
 Infected 580 (67) 756 (76)
 Non-infected 279 (31) 231 (23)
 Unknown 11 (1) 4 (<1)
On ART 241 (42) 369 (48) 0.027
CD4 count, cells/mm3, mean (95%CI) 294 (274–314) 319 (302–321) 0.065
CD4 count, cells/mm3, median [IQR] 251 [107–429] 294 [149–454] 0.013
CD4 category, cells/mm3 0.001
 <200 222 (38) 240 (32)
 201–350 120 (21) 210 (28)
 >350 182 (31) 281 (37)
 Missing CD4 count 56 (10) 25 (3)
Presenting with TB symptoms
 Cough 750 (85) 816 (82) 0.083
 Fever 192 (22) 219 (22) 0.988
 Night sweats 295 (34) 293 (30) 0.065
 Weight loss 220 (25) 309 (31) 0.004
POC = point of care; HIV = human immunodeficiency virus; ART =antiretroviral therapy; CI = confidence interval; IQR = interquartile range; TB 
= tuberculosis.
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Table 2
Factors associated with time to initiation of anti-tuberculosis treatment among Xpert-positive individuals
Univariate Multivariate
HR (95%CI) P value aHR (95%CI) P value
Xpert placement
 POC Reference
 Laboratory 0.45 (0.33–0.61) <0.001 0.45 (0.33–0.61) <0.001
Sex
 Male Reference Reference
 Female 1.0 (0.75–1.3) 0.995 1.0 (0.78–1.4) 0.761
Age category, years
 <30 Reference Reference
 30–45 0.97 (0.70–1.3) 0.863 1.1 (0.78–1.5) 0.604
 >45 0.79 (0.49–1.2) 0.306 0.85 (0.53–1.4) 0.490
HIV
 Negative Reference Reference
 Positive 0.77 (0.56–1.1) 0.144 0.77 (0.54–1.1) 0.140
 Unknown 0.32 (0.04–2.4) 0.265 0.42 (0.06–3.1) 0.401
ART
 Not on ART Reference
 On ART 1.2 (0.72–1.9) 0.539
CD4 category,* cells/mm3
 <200 Reference
 201–350 1.2 (0.73–1.9) 0.493
 >350 0.92 (0.52–1.6) 0.774
*
Excludes 14 HIV-infected individuals with missing CD4 count.
HR = hazard ratio; CI = confidence interval; aHR = adjusted HR; POC = point of care; HIV = human immunodeficiency virus; ART =antiretroviral 
therapy.
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Table 3




n/N (%) P value
Total errors 32/870 (4) 77/991 (8) <0.001
Error on initial Xpert
 Invalid 32/32 (100) 34/77 (44)
 Leaked — 33/77 (43)
 Rejected* — 10/77 (13)
Repeated with Xpert 32/32 (100) 33/77 (43) <0.001
Result on Xpert repeat
 Positive 6/32 (19) 3/33 (9)
 Negative 26/32 (81) 16/33 (48)
 Invalid — 2/33 (6)
 Leaked — 1/33 (3)
 Rejected — 11/33 (33)
Repeated with Xpert, smear or culture 32/32 (100) 41/77 (53) <0.001
*
A sample that was incorrectly rejected as having been submitted within 60 days of a sample with a valid Xpert result (e.g., the sample was 
rejected although it was a repeat after an error result).
POC = point of care.
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